• Seer disclosed preliminary results already presented at the 2026 ASMS meeting on AI-driven plasma proteomics for multi-cancer screening.
• Data from a collaboration with Korea University suggest the Proteograph platform can support large, consistent datasets suited to AI-based cancer detection research.
• The work points to potential screening models that use more of the underlying mass spectrometry signal than traditional approaches, aiming to improve disease-pattern detection.
• The study analyzed more than 5,500 plasma samples across multiple cancers and healthy controls, with plans to expand to more than 20,000 samples.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220700PRIMZONEFULLFEED9750222) on June 22, 2026, and is solely responsible for the information contained therein.